Cornea

The grading scales were compiled with the goals of achieving conciseness and the ability to provide clear drug-dose-modification recommendations compared with the previous ocular CTCAE scale.

EndoArt is an artificial cornea endothelial layer made of a sterile biocompatible material, acrylic hydrophilic. According to the company it is the first synthetic implant to treat corneal edema.

The procedure was conducted as part of the company’s ongoing phase 1 clinical trial.

Surgeons reflect on milestones that have redefined patient care—and share a glimpse of the advances that promise to shape the next era of eye health.

Host Deborah Ristvedt, DO, is joined by Marguerite B. McDonald, MD, FACS, to discuss her journey with pioneering contributions to ophthalmology, patient-centered care, leadership, and guidance for the next generation.

Veligrotug is an intravenously delivered, anti-insulin-like growth factor-1 receptor (IGF-1R) antibody for the treatment of thyroid eye disease (TED).

Clinicians discuss how the treatment compares with epi-off cross-linking, what may shape adoption, and how patient outcomes could improve.

Ophthalmologists discuss topography-guided techniques, long-term corneal health, and emerging technologies set to transform refractive surgery.

Chiu discusses factors affecting adoption of the FDA-approved epi-on therapy, from clinic setup to insurance coverage, while highlighting its safety and efficacy.

Rajpal shares his perspectives on the newly FDA-approved treatment, clinical benefits, and its potential impact on keratoconus management.

The trial evaluated the safety, efficacy, and tolerability of AURN001 in patients with corneal edema secondary to corneal endothelial dysfunction.

The incision-free therapeutic for keratoconus is expected to be commercially available in early 2026, according to the company.

The epithelium-on cross-linking modality is designed to enable simultaneous, bilateral keratoconus treatment, according to Epion Therapeutics.

Additionally, the company plans to perform cash-saving actions, including a workforce reduction.

OKYO Pharma advances urcosimod for neuropathic corneal pain, targeting a new clinical trial to optimize treatment and registration pathways.

Mark your calendars: On September 26 and 27, 2025, the Ophthalmology Times and Optometry Times EyeCon 2025 conference will convene at the Margaritaville Hollywood Beach Resort in Hollywood, Florida.

Viridian plans to submit a biologics license application (BLA) for VRDN-003 by year-end 2026.

In addition to Thompson joining the board of directors, EyeCool also announced the members joining its newly formed medical advisory board (MAB).

Marguerite B. McDonald, MD, FACS, shares a front-row view of ophthalmology’s “revolution with a capital R."

Robotic laser arcuate incisions reduce variability and residual astigmatism.

The primary end point of the trial was complete resolution of debris after 6 weeks of twice-daily dosing.

Funding will be specifically used to accelerate the clinical development of urcosimod (formerly called OK-101).